目的探讨磷脂酰肌醇蛋白聚糖.3(GPC3)在两种最常见肺癌病理类型鳞癌和腺癌中的不同表达及其与预后的关系。方法肺鳞癌和腺癌病人共48名,肝癌对照病人10名,采用免疫组织化学方法检测肺癌组织及其癌旁组织中GPC3蛋白的表达。应用Kaplan-Meier法进行生存分析。结果肺癌中的GPC3蛋白总表达率29.2%(14/48)。GPC3在肺癌旁组织中不表达。GPC3蛋白在肺鳞癌中的阳性率为54.5%(12/22),在肺腺癌中的阳性率为7.7%(2/26),肺鳞癌中的GPC3蛋白表达明显高于肺腺癌(P〈0.01)。在阳性表达的肺癌样本中,肺鳞癌与肺腺癌有淋巴结转移者和低分化组GPC-3均表达更显著。肺癌与肝癌的GPC3蛋白表达特点不同。Kaplan-Meier生存分析显示GPC3蛋白与预后无关。结论GPC3蛋白肺鳞癌患者表达更高,提示其可作为潜在候选标记物检测肺鳞癌。
Objective To study the different expressions of glypican-3 in lung squamous cell carcinoma and adenocarcinoma and explore the association of glypican-3 with the prognosis of the patients. Methods Glypican-3 expression was detected immunohistochemically in the tumor tissues and adjacent tissues from 48 cases of lung squamous cell carcinoma and Kaplan-Meier method and log-rank test were used for survival analysis of the patients. Results Glypican-3 expression was detected in the tumor tissues in 29.2% (14/48) of the cases, but not in the adjacent tissues. Of the 22 patients with lung squamous cell carcinoma, 12 (54.5%) showed positive glypican-3 expression in the tumor tissue, a rate significantly higher than that in patients with lung adenocarcinoma [7.7% (2/26), P〈0.01]. In all the glypican-3-positive cases, the tumor tissues showed stronger glypican-3 expression in cases with lymph node metastasis or poor tumor differentiation. Kaplan-Meier survival analysis did not indicate a significant correlation of glypican-3 expression with the prognosis of the lung cancer patients. Conclusion Patients with lung squamous cell carcinoma have higher glypican-3 expressions in the tumor tissues than those with lung adenocarcinoma, suggesting the value of glypican-3 protein as a potential marker to detect lung squamous cell carcinoma.